References
- Balasch J., Gomez F., Casamitjana R., Carmona F., Rivera F., Vanrell J. A. Pituitary-ovarian suppression by the standard and half-doses of D-Trp-6-luteinizing hormone-releasing hormone depot. Hum. Reprod. 1992; 7: 1230–4
- Drnowski W. P. Danazol-induced pseudo-menopause in the management of endometriosis. Clin. Obstet. Gynecol. 1988; 31: 829–39
- Balasch J., Jové I. C., Moreno V., Civico S., Puerto B., Vanrell J. A. The comparison of two gonadotropin-releasing hormone agonists in an in vitro fertilization program. Fertil. Sterii 1992; 58: 991–4
- Seifer D. B., Thornton K. L., DeCherney A. H., Lavy G. Early pituitary desensitization and ovarian suppression with leuprolide acetate is associated with in vitro fertilization-embryo transfer success. Fertil. Sterii 1991; 56: 500–4
- Penzias A. S., Lee G., Seifer D. B., Shamma F. N., De Cherney A. H., Reindollar R. H., et al. Aberrant estradiol flare despite gonadotropin-releasing hormone-agohist-induced suppression is associated with impaired implantation. Fertil. Steril 1994; 61: 558–60
- Jutras M. L. Estrogen-progestin combinations. Handbook of Drug Therapy in Reproductive Endocrinology and Infertility, M. E. Rivlin. Little, Brown, Boston 1990; 44–59
- Barbieri R. L., Ryan K. J. Danazol: endocrine pharmacology and therapeutic applications. Am. J. Obstet. Gynecol. 1981; 141: 453–63
- Droesch K., Barbieri R. L. Ovarian hyperstimulation syndrome associated with the use of the gonadotropin-releasing hormone agonist leuprolide acetate. Fertil. Steril 1994; 62: 189–90